Arcutis Biotherapeutics, Inc. ARQT
We take great care to ensure that the data presented and summarized in this overview for Arcutis Biotherapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARQT
View all-
Jennison Associates LLC12.2MShares$117 Million0.08% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$84.3 Million4.57% of portfolio
-
State Street Corp Boston, MA8.78MShares$84.3 Million0.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.88MShares$75.6 Million3.34% of portfolio
-
Rubric Capital Management LP New York, NY7.51MShares$72.1 Million2.54% of portfolio
-
Polar Capital Holdings PLC London, X06.89MShares$66.1 Million0.43% of portfolio
-
Black Rock Inc. New York, NY6.66MShares$63.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.17MShares$49.6 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA4.64MShares$44.6 Million0.02% of portfolio
-
Gilder Gagnon Howe & CO LLC New York, NY4.23MShares$40.7 Million0.54% of portfolio
Latest Institutional Activity in ARQT
Top Purchases
Top Sells
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Insider Transactions at ARQT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2024
|
Bhaskar Chaudhuri Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,139
+1.16%
|
-
|
|
Jun 14
2024
|
Halley E Gilbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,139
+35.0%
|
-
|
|
Jun 14
2024
|
Sue Jean Lin Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,139
+34.65%
|
-
|
|
Jun 14
2024
|
Neha Krishnamohan Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,139
+39.17%
|
-
|
|
Jun 14
2024
|
Terrie Curran Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,139
+35.0%
|
-
|
|
Jun 14
2024
|
Patrick J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,139
+35.0%
|
-
|
|
Jun 14
2024
|
Howard G. Welgus Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,139
+5.32%
|
-
|
|
Jun 14
2024
|
Keith R Leonard Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,139
+35.0%
|
-
|
|
Jun 04
2024
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.81%
|
$80,000
$8.01 P/Share
|
|
Jun 04
2024
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.73%
|
$10,000
$1.68 P/Share
|
|
May 30
2024
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
23,000
-9.88%
|
$184,000
$8.75 P/Share
|
|
May 30
2024
|
Patrick Burnett Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,000
+8.99%
|
-
|
|
May 29
2024
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
49,952
-19.23%
|
$399,616
$8.72 P/Share
|
|
May 28
2024
|
Masaru Matsuda See Remark |
SELL
Open market or private sale
|
Direct |
1,775
-0.93%
|
$15,975
$9.01 P/Share
|
|
May 27
2024
|
Masaru Matsuda See Remark |
BUY
Grant, award, or other acquisition
|
Direct |
4,875
+2.5%
|
-
|
|
May 17
2024
|
Larry Todd Edwards SVP Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,640
-5.16%
|
$61,120
$8.98 P/Share
|
|
May 16
2024
|
Larry Todd Edwards SVP Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+28.85%
|
-
|
|
May 02
2024
|
Matthew Richard Moore SVP and Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,681
-3.12%
|
$37,448
$8.74 P/Share
|
|
May 02
2024
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
9,555
-3.55%
|
$76,440
$8.74 P/Share
|
|
May 02
2024
|
Masaru Matsuda See Remark |
SELL
Open market or private sale
|
Direct |
5,016
-2.63%
|
$40,128
$8.74 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.24M shares |
|---|---|
| Open market or private purchase | 101K shares |
| Bona fide gift | 13.1K shares |
| Exercise of conversion of derivative security | 92.5K shares |
| Bona fide gift | 13.1K shares |
|---|---|
| Open market or private sale | 160K shares |